FILE PHOTO: Mayor of London Sadiq Khan speaks during an interview with Reuters at an event to promote the start of London Tech Week, in London, Britain, June 10, 2019. REUTERS/Dylan Martinez/File Photo
LONDON (Reuters) - U.S. President Donald Trump once again criticized London Mayor Sadiq Khan on Saturday, saying he is a “disaster” and will “only get worse” after three people were slain in the city in less than 20 hours.
Trump retweeted a tweet by the right-wing commentator Katie Hopkins who called London “stab city” and said “this is Khan’s Londonistan,” a phrase used to describe the city’s failure to tackle Muslim extremists.
“LONDON needs a new mayor ASAP. Khan is a disaster - will only get worse!” Trump said on Twitter.
Trump called Khan, a Muslim of Pakistani heritage, a “stone-cold loser” earlier this month after the mayor criticized the British government for inviting Trump for a state visit and compared him to 20th century fascists.
Trump’s feud with Khan dates back several years. Khan has criticized Trump’s effort to ban travelers from Muslim countries, while the president has castigated the mayor for his handling of a 2017 terrorist attack on the London bridge that killed 11 people.
Reporting By Andrew MacAskill; Editing by Bill Trott
PARIS (Reuters) - NATO faces significant costs if it does not act soon to choose a successor for its ageing fleet of 14 Boeing E-3A Airborne Warning & Control System (AWACS) surveillance aircraft, often called the alliance’s “eyes in the sky”, senior officials said.
FILE PHOTO: A NATO AWACS (Airborne Warning and Control Systems) aircraft approaches the Air Base number 5 during the Real Thaw 2018 exercise in Monte Real, Portugal February 6, 2018. REUTERS/Rafael Marchante/File Photo
Michael Gschossmann, general manager of the North Atlantic Treaty Organization agency that manages the AWACS fleet, said he expected to finalize by December a $750 million contract with U.S. arms maker Boeing Co to extend the life of the aircraft through 2035, with $250 million more earmarked for design, spare parts and testing.
But he said it was critical to decide quickly how to replace the 1979/1980-era airplanes, with their distinctive radar domes on the fuselage, or NATO would need to take costly steps to keep them flying even longer.
“We have to get moving on this. We have to ensure that the studies move along quickly. We need a reality check,” he said.
The AWACS planes are among the few military assets owned and operated by NATO, rather than individual states. They are used to conduct missions such as air policing, support for counter-terrorism operations, evacuations, and crisis response.
Gschossmann told Reuters NATO could follow the lead of member states Britain and Turkey in purchasing the E-7, a newer radar plane also built by Boeing. Those aircraft, he said, were large enough to add potential new capabilities, such as operating drones for expanded surveillance, in coming years.
“We have to ensure that we acquire a system that has growth potential, but that also – for financial and time reasons – is based on existing capabilities,” he said.
NATO is considering the AWACS replacement issue as part of a broader study of surveillance, but the process has dragged out given rapidly changing threats and newly emerging capabilities.
France and the United States also operate E-3A aircraft and could potentially buy E-7 planes in coming years, which could lower costs by generating larger order quantities.
“Why don’t we bet on the proven technology that we already have in the E-7 and provide NATO with a certain number of those aircraft? That would give us a basic capability that could be expanded in the future,” he said.
George Riebling, deputy general manager of the agency and a former senior U.S. official, said NATO was running out of time.
“If you don’t have an idea of what you’re going to do to replace NATO AWACS, then the ‘F’ in Final Lifetime Extension Programme (FLEP) can’t stand for final,” he said.
“There will be things we need to do to the NATO E-3A fleet to keep it flying past 2040.”
The FLEP program will update the aircraft’s mission system, as well as the processors for its electronic support measures (ESM) antenna. But it does not cover the radar itself, which would have doubled the cost.
Reporting by Andrea Shalal; Editing by Andrew Cawthorne
Cuban migrants return to Mexico from the United States to await their court hearing for asylum seekers as part of the legal proceedings under a new policy established by the U.S. government, in Ciudad Juarez, Mexico June 14, 2019. REUTERS/Jose Luis Gonzalez
EL PASO, Texas (Reuters) - The U.S. government on Thursday began ramping up the pace of returns of asylum seekers to Mexico to wait out their U.S. court hearings by sending around 200 migrants back through the El Paso, Texas, port of entry, according to a Mexican official.
The increase from around 100 migrants a day is the first sign of expansion of a Trump administration policy known as the Migrant Protection Protocols, said Luis Carlos Cano, a spokesman for Mexico’s national immigration agency in Ciudad Juarez, across the border from El Paso. The program began in January and was meant to expand as part of a deal to stave off tariffs on Mexican goods.
Reporting by Julio-Cesar Chavez in El Paso, Texas; Editing by Leslie Adler
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann
(This June 10 story deletes paragraph 9 to clarify that retreatment with Polivy has not been studied.)
(Reuters) - The U.S. Food and Drug Administration on Monday granted earlier-than-expected approval to Roche Holding AG’s antibody- Polivy for treatment of patients with advanced lymphoma.
Polivy was approved in combination with Roche’s older drug Rituxan and a chemotherapy agent for adult patients with advanced diffuse large B-cell lymphoma (DLBCL) whose cancer has worsened despite at least two previous lines of therapy.
Antibody-drug conjugates are designed to deliver a toxic chemotherapy directly to tumors. Roche said the average U.S. list price for a four-month course of Polivy would be $90,000. Rituxan is priced at $39,500 for four months.
Wall Street analysts estimate Polivy sales at nearly $1 billion by 2024, according to IBES data from Refinitiv.
Side effects seen in studies of Polivy included low blood cell counts, nerve damage, fatigue and pneumonia, the FDA said in a statement.
Cell therapies Yescarta, from Gilead Sciences Inc and Kymriah, sold by Novartis AG, are also approved for patients with advanced DLBCL.
Dr. Matthew Matasar, a hematologist at New York’s Memorial Sloan Kettering Cancer Center who was involved in the development of Polivy, said the drug could be an option for some patients to try before determining whether they need to move on to CAR-T treatments.
Roche estimates that nearly 25,000 new cases of DLBCL, a type of non-Hodgkin’s lymphoma (NHL), will be diagnosed in the United States this year. NHL, which is one of the most common cancers, accounts for about 4% of all types of cancers in the United States, according to the American Cancer Society. Continued approval for the treatment may depend on data from a confirmatory trial, Roche said. The FDA’s accelerated approval program allows conditional approval of a medicine that fills an unmet medical need for a serious condition.
Reporting by Aakash Jagadeesh Babu in Bengaluru and Deena Beasley in Los Angeles; Editing by James Emmanuel and Lisa Shumaker
WASHINGTON (Reuters) - U.S. lawmakers on Thursday responded to the crisis in Hong Kong over a proposed extradition law with China by introducing legislation that would require the U.S. government to justify the continuation of special treatment for the territory.
Protesters hold signs following a day of violence over a proposed extradition bill, outside the Legislative Council building in Hong Kong, China, June 13, 2019. REUTERS/Jorge Silva
The bipartisan Senate legislation, sponsored by several senior senators, would require the U.S. secretary of state to issue an annual certification of Hong Kong’s autonomy to justify special treatment under the U.S. Hong Kong Policy Act of 1992.
The proposed law, introduced by Republican Senator Marco Rubio and Democratic Senator Ben Cardin, would also require the U.S. president to identify those responsible for the abduction of booksellers and other individuals from Hong Kong and subject them to U.S. sanctions.
In Beijing on Friday, the foreign ministry expressed “extreme dissatisfaction” with the proposed U.S. bill, calling it “irresponsible carping and crude interference”.
China called on the United States “to give up its delusions of creating chaos in Hong Kong, stop pushing the proposed bill and to stop interfering in China’s domestic affairs,” spokesman Geng Shuang told a regular media briefing.
The bill would also require the president to issue a strategy to protect U.S. citizens and business from the effects of a revised extradition law and the U.S. Commerce Department to issue an annual report assessing whether Hong Kong was adequately enforcing U.S. and U.N. sanctions, particularly those on Iran and North Korea.
In addition, the legislation would make clear that Hong Kong citizens should not be denied visas to the United States if they were arrested or detained in connection with protest activity there.
The legislation was expected to be introduced to the House on Thursday.
Scuffles broke out between demonstrators and police in Hong Kong on Thursday as hundreds of people persevered with a protest against the extradition law a day after police fired tear gas and rubber bullets to break up big crowds.
Wednesday’s protests around the city’s legislature forced the postponement of debate on the bill, which many in Hong Kong fear will undermine freedoms and confidence in the commercial hub.
Reporting by David Brunnstrom; Additional reporting by Huizhong Wu; Editing by Steve Orlofsky
WASHINGTON (Reuters) - Jon Stewart, the popular former host of the late-night comedy program The Daily Show, criticized members of Congress for not attending a hearing on Tuesday on renewing funding for a program that provides health care to first responders who were sickened responding to the Sept. 11 attacks.
“Sick and dying, they brought themselves down here to speak and no one,” Stewart said, pointing to a mostly empty dais. “Shameful, it’s an embarrassment to the country and a stain on this institution. You should be ashamed of yourselves for those who aren’t here but you won’t be because accountability doesn’t appear to be something that occurs in this chamber.”
Stewart was testifying before the Judiciary Committee’s Subcommittee on the Constitution, Civil Rights and Civil Liberties about a renewal of the 9/11 first responders health care fund. Most of the panel’s 14 members were not in attendance.
“Where are they? It would be one thing if their callous indifference and rank hypocrisy was benign, but it’s not,” Stewart said. “Their indifference cost these men and women their most valuable commodity, time, one thing they’re running out of.”
The fund, originally approved for five years in 2010, provides medical treatment for emergency responders sickened by toxic dust inhaled at the World Trade Center site in New York in the days following the attack.
Republicans had balked at the price of the original legislation and as a compromise at the time, Democrats agreed to authorize the fund only for five years and cover the cost with an excise tax. That has set up a fight every five years to get Congress to renew the program.
Stewart criticized Congress for continuing to require the fund be renewed every five years - pointing to the panel’s top Republican, Representative Mike Johnson, for saying that Congress has to balance other emergencies as well.
“I’m pretty sure what’s going to happen five years from now, more of these men and women are going to get sick and they are going to die and I am awfully tired of hearing that it’s a 9/11 New York issue,” Stewart said. “Al-Qaeda didn’t shout death to Tribeca.”
Reporting by Ginger Gibson; Editing by Dan Grebler
